Regulation of smooth muscle contraction by monomeric non‐RhoA GTPases by Li, Bingsheng et al.
R E V I EW AR T I C L E
Regulation of smooth muscle contraction by monomeric non-
RhoA GTPases
Bingsheng Li | Ruixiao Wang | Yiming Wang | Christian G. Stief |
Martin Hennenberg
Department of Urology, University Hospital,
LMU Munich, Munich, Germany
Correspondence
Prof. Dr. Martin Hennenberg, Urologische
Klinik und Poliklinik, University Hospital, LMU




Smooth muscle contraction in the cardiovascular system, airways, prostate and lower
urinary tract is involved in the pathophysiology of many diseases, including cardio-
vascular and obstructive lung disease plus lower urinary tract symptoms, which are
associated with high prevalence of morbidity and mortality. This prominent clinical
role of smooth muscle tone has led to the molecular mechanisms involved being sub-
jected to extensive research. In general smooth muscle contraction is promoted by
three major signalling pathways, including the monomeric GTPase RhoA pathway.
However, emerging evidence suggests that monomeric GTPases other than RhoA
may be involved in signal transduction in smooth muscle contraction, including Rac
GTPases, cell division control protein 42 homologue, adenosine ribosylation factor
6, Ras, Rap1b and Rab GTPases. Here, we review these emerging functions of non-
RhoA GTPases in smooth muscle contraction, which has now become increasingly
more evident and constitutes an emerging and innovative research area of high
clinical relevance.
1 | INTRODUCTION
Smooth muscle contraction in the cardiovascular system, airways,
lower urinary tract and prostate is primarily involved in the patho-
physiology of many diseases, which have a high mortality and are also
causing high individual and socio-economic burden, such as in cardio-
vascular and obstructive lung diseases plus lower urinary tract symp-
toms. Accordingly, inhibition of smooth muscle contraction is an
important strategy in medical treatment of these diseases, which
together affecting billions of patients worldwide. In line with the
prominent role of smooth muscle tone in health, disease and therapy
the molecular mechanisms of contraction and relaxation were and are
the subject of continuous research.
Smooth muscle contraction is induced by receptors, by mechani-
cal and other stimuli, which subsequently activate intracellular,
contraction-mediating signalling pathways. These pro-contractile sig-
nalling pathways all end in a few final mechanisms, which are absolute
prerequisites for smooth muscle contraction, including myosin light
chain (MLC) phosphorylation, actin polymerization, organization and
attachment of filaments to membranes and anchoring of cells to the
extracellular matrix (Kim, Appel, Vetterkind, Gangopadhyay, &
Morgan, 2008; Puetz, Lubomirov, & Pfitzer, 2009). Intracellular signal-
ling pathways resulting in contraction include calcium-dependent
mechanisms that parallel increases of calcium sensitivity, which was
realized early during the exploration of smooth muscle contraction.
The role of the small monomeric GTPase RhoA for signal transduction
promoting vascular smooth muscle contraction by immediate
increases of calcium sensitivity has been recognized since 1992
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(Hirata et al., 1992). In 1997, Rho kinase was identified as an impor-
tant mediator of smooth muscle contraction, which increases calcium
sensitivity independently of PKC (Uehata et al., 1997). These discover-
ies were followed by numerous studies describing activation of Rho
kinase by the small monomeric GTPase, RhoA, and on how this path-
way results in smooth muscle contraction in different organs (Chiba,
Matsusue, & Misawa, 2010; Christ & Andersson, 2007; Hennenberg,
Trebicka, Sauerbruch, & Heller, 2008; Loirand & Pacaud, 2014;
McMurtry, Abe, Ota, Fagan, & Oka, 2010; Rattan, Phillips, &
Maxwell, 2010). Thus, receptor-dependent smooth muscle contraction
is assumed to be mediated by activation of basically three intracellular
signalling pathways, which are shared by smooth muscle in any smooth
muscle-rich tissue (Somlyo & Somlyo, 2000, 2003):- (i) a calcium-
dependent pathway activated by inositol-1,4,5-triphosphate (IP3)
resulting in receptor-dependent activation of phosphoinositide-
specific PLC, (ii) increase of calcium sensitivity mediated by activation
of PKC by DAG resulting from PLC activation and (iii) increase of cal-
cium sensitivity mediated by receptor-dependent activation of
RhoA/Rho kinase (Somlyo & Somlyo, 2000, 2003). Finally, these mech-
anisms promote contraction by increasing MLC phosphorylation,
resulting from activation ofMLC kinase (MLCK) by calcium-dependent
pathways and from inactivation of MLC phosphatase by PKC- and Rho
kinase-dependent pathways (Somlyo & Somlyo, 2000, 2003).
Apart from RhoA, the superfamily of small monomeric GTPases
includes a panel of more than 100 further members, belonging to at
least five different families (Takai, Sasaki, & Matozaki, 2001). Emerging
evidence suggests that monomeric GTPases other than RhoA (herein
referred to as “non-RhoAGTPases”) may be involved in signal transduc-
tion in smooth muscle contraction as well, including Rac GTPases, the
cell division control protein 42 homologue (Cdc42) and GTPases from
the Ras, Rap and adenosine ribosylation factor (ARF) families. Here, we
review the emerging function of these non-RhoA GTPases for smooth
muscle contraction. As the role of RhoA for smooth muscle contraction
has been already intensively described elsewhere, we will focus here
on non-RhoA GTPases and only outline the already previously
established mechanisms of smooth muscle contraction. For some
organs, including urethral or vascular smooth muscle in the corpus
cavernosum, a role of RhoA has been proven for smooth muscle con-
traction, but to the best of our knowledge not yet for other monomeric
GTPases (Malmqvist, Hedlund, Sward, & Andersson, 2004; Teixeira,
Jin, Priviero, Ying, & Webb, 2007; H. Wang, Eto, Steers, Somlyo, &
Somlyo, 2002). Certainly, this does not reflect lack of functions of non-
RhoA GTPases in smooth muscle contraction of these tissues. Rather,
missing evidence is probably attributed lack of investigations, as these
tissues are in fact relatively neglected in basic research.
2 | ESTABLISHED MECHANISMS OF
SMOOTH MUSCLE CONTRACTION
In general, smooth muscle contraction depends essentially on several
prerequisites, which are MLC phosphorylation, actin assembly to fila-
ments, filament organization of and attachment to cell membranes,
and anchoring of cells in tissues and extracellular matrix (Kim
et al., 2008; Puetz et al., 2009). These processes are endpoints of sig-
nalling pathways, which promote smooth muscle contractions and
which are activated by receptors or receptor-independent stimuli
(Puetz et al., 2009). Thus, these signalling pathways transduce extra-
cellular signals induced by hormonal, neurogenic, autocrine, humoral,
mechanical or other stimuli to the basic contraction machinery of
smooth muscle cells.
Agonist-induced smooth muscle contraction starts with activation
of GPCRs (Somlyo & Somlyo, 2000, 2003). Receptor activation by
corresponding ligands causes conformational changes of the receptor,
resulting in dissociation of receptor-associated heterotrimeric G pro-
teins from receptors and of the Gα subunits from Gβ and Gγ subunits.
Subsequently, Gα subunits (Gαq/11, Gα12 and/or Gα13) of these G pro-
teins activate PLC and RhoA. PLC hydrolyses phosphatidylinositol-
4,5-bisphosphate, resulting in the formation of the second messen-
gers IP3 and DAG. IP3 opens Ca
2+ channels in the sarcoplasmic reticu-
lum, leading to depolarization of the membrane potential by elevation
of the otherwise low cytosolic Ca2+ concentration. Consequently,
voltage-gated calcium channels in the cell membrane are opened,
leading to a massive (capacitative) Ca2+ current from the extracellular
space into the cell, according to the concentration gradient of Ca2+.
This causes activation of Ca2+-dependent calmodulin and of
calmodulin-dependent MLCK, finally resulting in contraction by
enhanced MLC phosphorylation. This is paralleled by increases of cal-
cium sensitivity, being accomplished by two mechanisms, which both
increase MLC phosphorylation by inhibition of MLC phosphatase
(MLCP). First, DAG activates PKC, which activates MLCP by direct
phosphorylation of its myosin targeting subunit (MYPT1) or indirectly
by phosphorylation-mediated inactivation of the MLCP inhibiting fac-
tor, CPI-17. Secondly, Gα subunits activate RhoA, which then acti-
vates Rho kinase, followed by phosphorylation-mediated inactivation
of MLCP.
Activation and deactivation of monomeric GTPases underlie uni-
versal principles, although little is known about the precise players
involved in the context of smooth muscle tone regulation (Cherfils &
Zeghouf, 2013). Activation of monomeric GTPases is achieved by gua-
nine nucleotide exchange factors (GEFs; Cherfils & Zeghouf, 2013;
Puetz et al., 2009). It has been assumed that Gαq/11, Gα12 and Gα13
subunits associated to contractile smooth muscle receptors activate
RhoA by activation of guanine nucleotide exchange factors. However,
the identity of these guanine nucleotide exchange factors still remains
uncertain in the context of smooth muscle contraction (Puetz
et al., 2009). Possible candidates may be LARG, PDZ-RhoGEF, p115
RhoGEF, Vsm-RhoGEF and SmgGDS (Puetz et al., 2009). These gua-
nine nucleotide exchange factors occur in smooth muscle, whereas
more than 70 Rho-activating guanine nucleotide exchange factors
may exist in total in different cell types (Puetz et al., 2009). Guanine
nucleotide exchange factors promote the exchange of guanosine
diphosphate (GDP) bound to GTPases in their inactive state to GTP,
what is a major step in GTPase activation (Cherfils & Zeghouf, 2013;
Puetz et al., 2009). In addition, the activation step is associated with a
translocation of the inactive GTPases being located to cytosolic
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regions to the cell membrane (Puetz et al., 2009). This is accomplished
by release of guanine nucleotide dissociation inhibitors from the inac-
tive GTPase (Cherfils & Zeghouf, 2013; Puetz et al., 2009). GTPase-
bound guanine nucleotide dissociation inhibitors keep the GTPase in
cytosolic membranes by binding to the hydrophobic membrane
anchors, so that their separation from the GTPase following activation
by guanine nucleotide exchange factors permits the translocation to
the membrane (Puetz et al., 2009). Finally, the GTPase will start to
hydrolyze the bound GTP to GDP following its activation, resulting in
its own inactivation (Puetz et al., 2009). GTP hydrolyzation and there-
fore inactivation of monomeric GTPases are accelerated by GTPase
activating proteins (Cherfils & Zeghouf, 2013; Puetz et al., 2009).
3 | RAC GTPASES IN SMOOTH MUSCLE
CONTRACTION
Of all non-RhoA GTPases taking part in regulation of smooth muscle
contraction, Rac GTPases are the best characterized. Rac occurs in
three different isoforms referred to as Rac1–3 (Takai et al., 2001). Rac
GTPases regulate not only important cellular functions including cell
cycle and growth in malignant and non-malignant cells but also cyto-
skeletal functions depending on correct actin assembly, such as lam-
ellipodia formation, motility and migration and including smooth
muscle cells (Marinkovic, Heemskerk, van Buul, & de Waard, 2015).
Evidence supporting a pro-contractile role of Rac has been obtained,
(i) for vascular, airway, lower urinary tract, prostate and gastrointesti-
nal smooth muscle; (ii) for different species; (iii) using pharmacological
and knockout approaches and (iv) using in vitro and in vivo models
(Table 1). In addition to a contraction-mediating role of Rac, an anti-
contractile role of Rac has been proposed for airway and vascular
smooth muscle (Table 1).
Many findings suggesting a role of Rac1 in smooth muscle con-
traction were obtained using small molecule inhibitors with presumed
specificity for Rac GTPases. Thus, increasing interest of Rac1 not only
in oncological context but also in vascular diseases resulted in the
development of Rac inhibitors. The first inhibitor with assumed speci-
ficity for Rac GTPases was NSC23766, which inhibits Rac GTPases by
inhibition of Rac-specific guanine nucleotide exchange factors (Akbar,
Cancelas, Williams, Zheng, & Zheng, 2006; Gao, Dickerson, Guo,
Zheng, & Zheng, 2004). Its selectivity may be higher for Rac1 than for
Rac2 or Rac3, but it does not inhibit RhoA or Cdc42 (Akbar
et al., 2006; Gao et al., 2004). Later on, it turned out that the specific-
ity of NSC23766 is in fact limited, as it acts as a competitive antago-
nist at muscarinic ACh receptors (Levay et al., 2013). With EHT1864
and EHop-016, two other small molecule inhibitors with assumed Rac
specificity were developed (Montalvo-Ortiz et al., 2012; Onesto,
Shutes, Picard, Schweighoffer, & Der, 2008; Shutes et al., 2007).
EHT1864 binds directly to Rac proteins and is unselective for all three
isoforms (Onesto, Shutes, Picard, Schweighoffer, & Der, 2008; Shutes
et al., 2007). Ehop-016 was developed on the basis of NSC23766 and
consequently acts by inhibition of Rac guanine nucleotide exchange
factors and preferentially inhibits Rac1 and Rac3 and also Cdc42 at
higher concentrations (Montalvo-Ortiz et al., 2012). Rac inhibition by
NSC23766 and EHT1864 is attained by different mechanisms, so that
NSC23766 may inhibit Rac GTPases indirectly by prevention of Rac
interaction with Rac-activating guanine nucleotide exchange factors,
whereas EHT1864 may inhibit Rac directly (Akbar et al., 2006; Gao
et al., 2004; Shutes et al., 2007). In addition to muscarinic receptor
antagonism of NSC23766, Rac-independent effects of NSC23766
and EHT1864 were proposed, as both compounds showed effects in
Rac1-deficient platelets if 100 μM were applied (Dütting et al., 2015).
Thus, at least at higher concentrations, Rac1-independent effects may
be expected by both of these compounds.
Rac-dependent actin organization and its involvement in actin-
dependent functions have been described already before first reports
suggested regulation of smooth muscle tone by Rac. Formation and
organization of actin filaments by Rac were observed in vascular
smooth muscle cells, so that the following discovery of Rac-
dependent smooth muscle tone regulation may not be completely sur-
prising (Bond, Wu, Sala-Newby, & Newby, 2008). The first study
reporting the role of Rac for smooth muscle tone suggested Rac-
mediated relaxation of airway smooth muscle (Roscioni et al., 2011).
Findings of that study suggested that muscarinic receptors deactivate
Rac during cholinergic airway smooth muscle contraction and that
relaxation of airway smooth muscle by the cAMP effector exchange
protein directly activated by cAMP (Epac) occurs by promotion of Rac
activity (Figure 1; Roscioni et al., 2011).
These initial findings are opposed by later studies, suggesting that
Rac promotes airway smooth muscle contraction rather than
TABLE 1 Summarized evidence for regulation of smooth muscle contractility by Rac GTPases
Rac1
Role Mechanism Evidence from Species
Vascular Pro- and anti-contractile PLC/Ca2+, possibly others Inhibitors, knockout Mouse, rat
Airway Pro- and anti-contractile Pro-contractile: Ca2+ sensitization;
anti-contractile: Epac
Inhibitors, knockout Human, mouse, rat
Prostate Pro-contractile not MLC, possibly actin Inhibitors Human
Urinary bladder Pro-contractile — Inhibitors, knockout Human, mouse, rat
Gastrointestinal Pro-contractile — Inhibitors, knockout Mouse
Note. Available findings have been categorized to role, assumed mechanisms of Rac-dependent regulation, basis of findings and species.
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counteracting it. Thus, EHT1864 and NSC23766 inhibited cholinergic
contractions of isolated airway preparations from humans, mice and
rats (Andre-Gregoire et al., 2017; Sakai, Kai, Sato, Ikebe, &
Chiba, 2018). The inhibitory effect was not restricted to cholinergic
contractions, EHT1864 also inhibited 5-hydroxytryptamine-induced
contractions of airway preparations from mice, and EHT1864 and
NSC23766 inhibited endothelin-1-induced contractions of airway tis-
sues from rats (Andre-Gregoire et al., 2017; Sakai et al., 2018). The
F IGURE 1 Proposed functions of Rac1 and Cdc42 in regulation of smooth muscle contraction. Rac1-mediated promotion of smooth muscle
contraction has been suggested for airway, vascular, prostate, bladder, and gastrointestinal smooth muscle. Rac1-dependent inhibition of smooth
muscle contraction has been suggested for airway and vascular smooth muscle. Illustration of proposed involved mechanisms has been simplified
to the lowest common denominator if different studies revealed different results. GTPases with a pro-contractile role are marked by green colour,
and GTPases with an anti-contractile function by red colour. Ca2+, calcium; sGC, soluble guanylate cyclase
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contraction-promoting role of Rac1 was confirmed by a knockout
model, methacholine-induced contractions in airway preparations in
mice with smooth muscle-specific knockout of Rac1 was reduced
compared with that in wild types (Andre-Gregoire et al., 2017). Con-
sidering the possible limitations of available small molecule inhibitors
outlined above, these findings using a knockout model may be of par-
ticular importance and point to the role of Rac1 as an isoform being
involved in Rac-mediated airways smooth muscle contraction.
In addition to contractility studies in vitro, the role of Rac for air-
way smooth muscle contraction was confirmed in vivo. Although mice
with smooth muscle-specific Rac1 deletion showed normal airway
function under basal conditions, pulmonary resistance raised by aero-
solized methacholine was lower in knock out mice compared with that
in wild type animals (Andre-Gregoire et al., 2017). In wild type mice,
but not in knockouts, the methacholine-induced airway response was
decreased by inhalation of NSC23766 (Andre-Gregoire et al., 2017).
Importantly, the efficacy of NSC23766 was similar to that of the
β2-adrenoceptor agonist salbutamol, the gold standard in experimen-
tal and clinical asthma treatment (Andre-Gregoire et al., 2017).
Similar to airway smooth muscle, evidence for the role of Rac1 in
promotion of vascular smooth muscle is based on studies using inhibi-
tors and knockout models in vitro and in vivo. In contractility studies
performed with rat aortic rings, NSC23766 inhibited contractions
induced by the α1-adrenoceptor agonist phenylephrine and contrac-
tions induced by 5-hydroxytryptamine (Shibata et al., 2015). Again, in
contractility assays, NSC23766 and EHT1864 inhibited contractions
of mouse aorta, saphenous artery and mesenteric artery induced by
phenylephrine (Rahman et al., 2014). Similarly, NSC23766 inhibited
α1-adrenoceptor mediated contractions induced by noradrenaline in
rat resistance vessels of the cremaster, assessed by confocal micros-
copy (Staiculescu et al., 2013). The role of Rac1 in contraction of
α1- adrenoceptor vasocontraction was confirmed by inhibition of
phenylephrine-induced contractions in contractility studies using
aorta, saphenous artery and mesenteric artery from mice with smooth
muscle-specific Rac1 knockout and after insertion of a dominant neg-
ative form of Rac1 into permeabilized rabbit femoral arteries (Rahman
et al., 2014; Shibata et al., 2015).
Apart from a principal role of Rac GTPases for vascular smooth
muscle contraction in non-diseased conditions, a role in vascular
hypercontractility of stroke-prone spontaneously hypertensive rats
has been suggested. Thus, whereas EHT1864 did not change phenyl-
ephrine contractions of mesenteric arteries from normotensive con-
trol rats, these were inhibited in vessels from hypertensive rats
(Harvey et al., 2017).
In addition to airway smooth muscle, diverging results were
reported concerning the role of Rac for vascular smooth muscle con-
traction. Whereas the studies summarized above suggest promotion
of vascular smooth muscle by Rac1, another study reported increases
of contractile responses to phenylephrine and the TXA2 analogue
U46619 in isolated mesenteric arteries from mice with inducible
smooth muscle-specific Rac1 knockout (André et al., 2014). This was
confirmed in vivo, as these mice developed hypertension, which was
due to increased vascular resistance but not due to changes in
diastolic BP or heart rate (André et al., 2014). Deeper analysis
supported the idea that these effects were mediated by disruption of
nitric oxide (NO)-induced cGMP production in vascular smooth mus-
cle cells, which usually induces smooth muscle relaxation and may
obviously be Rac-dependent (André et al., 2014).
In the lower urinary tract and prostate, the role of Rac GTPases
for smooth muscle contraction has been examined for the prostate
and bladder. NSC23766, EHT1864 and smooth muscle-specific Rac1
knockout all inhibited carbachol-induced bladder contractions in mice,
as shown by contractility measurements (Rahman et al., 2014). In
human prostate tissues, NSC23766 and EHT1864 inhibited
α1-adrenoceptor contractions induced by phenylephrine or noradren-
aline and neurogenic contractions induced by electric field stimulation
(Y. Wang et al., 2015). As α1-adrenoceptor antagonists are the
first-line option for medical treatment of lower urinary tract symp-
toms suggestive of benign prostatic hyperplasia, it is noteworthy that
the degree of inhibition of neurogenic contractions by EHT1864 and
NSC23766 resembles the efficacy of α1 antagonists under the same
conditions (Y. Wang et al., 2015). In addition to α1-adrenoceptors,
prostate smooth muscle contraction can be induced by activation of
endothelin and TXA2 receptors. In contrast to U46619-induced con-
tractions, which were inhibited by EHT1864 and NSC23766,
endothelin-1 induced contractions of human prostate tissues were
inhibited by EHT1864, but not by NSC23766 (Q. Yu, Gratzke, Wang,
Wang et al., 2019). Consequently, it has been proposed that this may
be attributed to divergent pharmacological profiles of both inhibitors
and/or to divergent receptor-specific regulation of these contractions,
which is incompletely understood (Q. Yu, Gratzke, Wang, Wang,
et al., 2019). As most patients included in this study may show benign
prostatic hyperplasia (BPH), it has been suggested that Rac-dependent
smooth muscle contraction is relevant for the development of lower
urinary tract symptoms suggestive of benign prostatic hyperplasia
(Y. Wang et al., 2015). Examinations using knockout or transgenic
models have not been performed to confirm the role of Rac GTPases
for prostate smooth muscle contraction. Nevertheless, such role
appears likely, considering the evidence from other organs summa-
rized above.
Regarding the urinary bladder, a pro-contractile role of Rac1 in
bladder smooth muscle has been confirmed using Rac1 knockout
mice, where contractions induced by carbachol and high-molar potas-
sium chloride were reduced to wild types (Rahman et al., 2014). In line
with these findings, NSC23766 and EHT1864 inhibited cholinergic
contractions of bladder tissues from wild type mice and neurogenic
and carbachol-induced contractions of bladder tissues obtained from
female and male patients undergoing radical cystectomy (B. Li
et al., 2020; Rahman et al., 2014). In both studies, inhibitory effects
of NSC23766 were, however, at least partially related to a Rac-
independent antagonism of muscarinic receptors by NSC23766, in
line with previous findings reporting this nonspecific feature of the
presumed Rac inhibitor (Levay et al., 2013; B. Li et al., 2020; Rahman
et al., 2014). Interestingly, the divergent pharmacological profiles of
NSC23766 and EHT1863 became further manifest by different
effects on TXA2 induced contractions, which were inhibited by
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EHT1864, but not NSC23766 in human bladder tissues from both
genders (B. Li et al., 2020). In rats with experimentally induced diabe-
tes, Rac1 expression was reported to be up-regulated in the detrusor,
what was paralleled by pronounced inhibition of carbachol-induced
contractions by NSC23766 (Evcim et al., 2015). According to the role
of detrusor contraction for bladder emptying in micturition, a possible
role of diabetes-related bladder dysfunction has been proposed
(Evcim et al., 2015).
Evidence suggesting the role of Rac1 for smooth muscle contrac-
tion in the gastrointestinal tract is still limited. At least, it has been
demonstrated that NSC23766, EHT1864 and smooth muscle-specific
Rac1 knockout reduce contractions of the ileum in contractility
studies (Rahman et al., 2014).
Findings suggesting Rac-mediated smooth muscle contractions
were completed by addressing the underlying mechanisms. Several
mechanisms have been suggested, which may diverge between
smooth muscle types or even within the same organ but may also
show overlapping features (Figure 1). The current understanding is
certainly still incomplete, as most studies focussed on one or few
mechanisms and did not systematically ruled out other possible mech-
anisms (Figure 1). Rac1 may be activated by contractile agonists, as
shown by application of cholinergic agonists in airway smooth muscle
cells and rat airway tissue or using phenylephrine in intact rat aortic
tissue (Andre-Gregoire et al., 2017; Sakai et al., 2018; Shibata
et al., 2015). Although Rac1 may activate p21 activated kinase 1 in
airway smooth muscle, this is not responsible for Rac-mediated airway
smooth muscle contraction, so that other mediators account for Rac-
dependent contraction (Andre-Gregoire et al., 2017). Studies
addressing relationship between Rac and calcium sensitization or
calcium-mediated contractions revealed conflicting results. Rac inhibi-
tors did not reduce MYPT1 phosphorylation in airway smooth muscle
cells, so that interference of Rac with calcium sensitivity was excluded
(Andre-Gregoire et al., 2017). Rather, experiments using inhibitors and
Rac1-deficient airway smooth muscle cells suggested that Rac1
induces contraction by PLC activation and subsequent activation of
calcium-dependent mechanisms (Andre-Gregoire et al., 2017). This
was confirmed by findings from aorta, saphenous artery and mesen-
teric artery from mice, suggesting that Rac promotes vascular smooth
muscle contraction by elevation of intracellular calcium, but not by
PKC-dependent mechanisms and probably not via Rho kinase
(Rahman et al., 2014). In contrast, contractility measurements and
phosphorylation analyses performed with airway and aorta tissues
from rats suggested the opposite, that is, that Rac inhibitors act by
inhibition of MLC phosphatase and calcium sensitization, but not
by inhibition of calcium-/MLCK-dependent mechanisms (Sakai
et al., 2018; Shibata et al., 2015). In airway smooth muscle, this may
involve PKC and Rho kinase, whereas involvement of PKC, but not
Rho kinase, has been suggested for rat aortic smooth muscle (Sakai
et al., 2018; Shibata et al., 2015). However, consistent with contradic-
tory findings regarding calcium sensitization or calcium-dependent
mechanisms, Rac inhibitors inhibited cholinergic and endothelin-1
induced MLC phosphorylation in rat airway tissues, as well as
phenylephrine-induced MLC phosphorylation in rat aortic tissues
(Sakai et al., 2018; Shibata et al., 2015). In prostate smooth muscle,
Rac-mediated contraction may be based on completely different
mechanisms, as NSC23766 or EHT1864 did not alter MLC phosphor-
ylation (Y. Wang et al., 2015). Rather, both inhibitors caused a break-
down of actin filaments, so that the role of Rac for regulation of actin
organization was proposed for prostate smooth muscle (Y. Wang
et al., 2015). Affecting contraction through different endpoint mecha-
nisms may not be unique for Rac1, as the same has been reported for
the RhoA/Rho kinase pathway. Thus, RhoA/Rho kinase are capable to
promote smooth muscle contraction by increasing MLC phosphoryla-
tion and also via actin organization (Amin et al., 2013).
Another topic of investigations was the mechanisms of Rac activa-
tion by guanine nucleotide exchange factors in smooth muscle cells.
Several proven and putative Rac guanine nucleotide exchange factors
exist, which may be cell and/or pathway specific. Application of knock-
out models in cell culture demonstrated that Rac1 is activated by p115
RhoGEF and kalirin, thus, at least two different guanine nucleotide
exchange factors in vascular smooth muscle cells (Singh, Janjanam, &
Rao, 2017; Wu et al., 2013). Whether this mechanism also takes place
outside cell culture, that is, in vascular smooth muscle of intact vessels
or also in smoothmuscle cells of other organs still remains open.
4 | RAS GTPASES IN SMOOTH MUSCLE
CONTRACTION
Ras GTPases are probably best characterized in oncologic context,
according to their role as central players in tumour growth, based on
Ras-mediated gene expression, proliferation and transformation (Takai
et al., 2001). Numerous studies proved additional functions, including
promotion of smooth muscle contraction (Table 2). First evidence
suggesting the role of Ras for mediating vascular smooth muscle con-
traction has been provided surprisingly early. Thus, in 1993, it has
been reported that activated H-Ras induces contraction at constant
calcium levels in permeabilized mesenteric micro-arteries from guinea
pigs (Satoh, Rensland, & Pfitzer, 1993). It was concluded that H-Ras
may promote vasocontraction by immediately increasing calcium sen-
sitivity (Figure 2; Satoh et al, 1993). Remarkably, this Ras function in
signal transduction mediating smooth muscle contraction has not been
pursued or confirmed thereafter. Instead, some later studies
suggested Ras-dependent regulation of smooth muscle contraction at
expression level rather than a direct, immediate impact of Ras-
mediated signal transduction on contractile endpoints.
Thus, in spontaneously hypertensive rats, captopril treatment for
12–18 weeks resulted in decreased phospho-MLC levels in mesen-
teric arteries, which was paralleled by decreased Ras expression (Hu,
Han, Gu, Piano, & de Lanerolle, 2007). The authors concluded that
decreased Ras activity was the reason for the reduced MLC content
(Hu et al., 2007). Certainly, such a causal relationship or correlation
could not be excluded but was not proven and was definitely lacking
after 24 weeks of captopril treatment (Hu et al., 2007).
Convincing evidence for Ras-mediated regulation of smooth mus-
cle tone was provided by a study addressing Rho kinase-dependent
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contraction in the internal anal sphincter of Ras knockout mice
(de Godoy et al., 2007). Notably, these results suggested an opposing
regulation, namely, antagonization of smooth muscle contraction by
interference with RhoA activity and expression of Rho kinase
(Figure 2; de Godoy et al., 2007). Thus, higher spontaneous tone of
internal anal sphincter in Ras knockout mice was associated with
decreased reactivity to the Rho kinase inhibitor Y27632, increased
membrane translocation of RhoA and higher protein expression of
Rho kinase 2 (de Godoy et al., 2007).
A similar concept suggested maintenance of Rho kinase expression
by Ras activity, which was confirmed by reduced contractility following
Rho kinase down-regulation and inhibition of Ras activity. In rat kidney
cells, Rho kinase expression is post-transcriptionally down-regulated
by sustained activation of the Ras/MAPK pathway (Pawlak &
Helfman, 2002). This down-regulationwas prevented by pharmacologi-
cal Ras inhibition (Pawlak & Helfman, 2002). Post-transcriptional
down-regulation of Rho kinase and subsequent loss of Rho kinase-
mediated vasocontraction contributes to vascular hypocontractility,
splanchnic vasodilation and finally portal hypertension in liver cirrhosis
(Hennenberg et al., 2006). Treatment of rats with experimentally
induced liver cirrhosis with sorafenib, which inhibits Ras and its down-
stream effectors, restored vascular Rho kinase expression and resulted
in increased splanchnic and systemic vascular resistance and finally an
improvement of portal hypertension (Hennenberg et al., 2009).
Together, these findings point to a Ras-dependent and organ-
specific regulation of smooth muscle contraction, which includes pro-
motion and reduction of contractility and takes place by Ras-mediated
alterations of Rho kinase expression.
5 | CDC42 IN SMOOTH MUSCLE
CONTRACTION
As RhoA and Rac GTPases, Cdc42 belongs to the Rho family of mono-
meric GTPases (Takai et al., 2001). Possibly due to its close relation-
ship to RhoA, Cdc42 has been considered quite early in the context of
smooth muscle contraction. Transfection of permeabilized isolated
dog tracheal rings with a dominant negative Cdc42 mutant reduced
acetylcholine-induced contractions of these tissues, proving a role of
Cdc42 for canine airway smooth muscle contraction (Table 2; Tang &
Gunst, 2004). To the best of our knowledge, however, this was the
only study directly reporting the role of CDC42 in smooth muscle
contraction, that is, by showing smooth muscle contraction of intact
tissues. Although other studies repeatedly suggested a similar role and
suggested involved mechanisms, this evidence stayed preliminary and
included demonstration of Cdc42 activation by contractile agonists
and Cdc42 induced actin organization in smooth muscle cells (Choi
et al., 2005; Fediuk, Sikarwar, Nolette, & Dakshinamurti, 2014; Q. F.
Li & Tang, 2009; Tang & Gunst, 2004; Tang, Zhang, & Gunst, 2005;
Zhang, Huang, & Gunst, 2016). Consequently, it has been assumed
that Cdc42 promotes smooth muscle contraction by actin polymeriza-
tion and filament organization but not via MLC phosphorylation
(Figure 1), what involves most probably Wiskott–Aldrich Syndrome
protein family members (Puetz et al., 2009).
6 | ADENOSINE RIBOSYLATION FACTOR
(ARF) 6 IN SMOOTH MUSCLE CONTRACTION
The family of ARF GTPases contains six members referred to as
ARF1–6. Various functions have been attributed to ARFs, including
cytoskeletal organization and actin remodelling (Donaldson, 2002;
Hongu & Kanaho, 2014; Humphreys, Davidson, Hume, Makin, &
Koronakis, 2013; Klein, Franco, Chardin, & Luton, 2006; Luton
et al., 2004; Schafer, D'Souza-Schorey, & Cooper, 2000). In fact, ARF6
promotes processes depending on correct actin assembly and cyto-
skeletal organization, including cell adhesion, migration and platelet
activation (Charles, Namkung, Cotton, Laporte, & Claing, 2016; Choi,
Karim, & Whiteheart, 2006; Hiroi, Someya, Thompson, Moss, &
Vaughan, 2006; Torii et al., 2010; Urban, Quick, Miller, Krcmery, &
Simon, 2016). In addition, ARF6 has been proposed as an intracellular
effector and regulator of GPCRs, which mediates receptor-induced
TABLE 2 Summarized evidence for regulation of smooth muscle contractility by GTPases other than RhoA and Rac
Smooth muscle type Role Mechanism Evidence Species
Cdc42 Airway Pro-contractile Actin Dominant negative
Cdc42 expression
Dog
H-Ras Vascular Pro-contractile Ca2+ sensitization Recombinant Ras Guinea pig
Ras Internal anal sphincter,
possibly also vascular








ARF6 Prostate Pro-contractile Not MLC, possibly actin Inhibitors Human
Rap1b Vascular Anti-contractile MYPT1/MLC phosphorylation Knockout Mouse





Note. Available findings for all indicated GTPases have categorized to smooth muscle type, role, assumed mechanims of GTPase-dependent regulation,
basis of findings and species.
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effects and takes part in post-translational modification of receptors
(Bourmoum, Charles, & Claing, 2016; Giguère et al., 2006;
Hennenberg et al., 2013; Hunzicker-Dunn, Gurevich, Casanova, &
Mukherjee, 2002). The best characterized and probably most common
GEF for ARF6 is cytohesin-2 (Hongu & Kanaho, 2014; Torii
et al., 2010; Torii et al., 2015). Effects of the cytohesin-2 inhibitor,
F IGURE 2 Proposed functions of Ras, ARF6, Rap1b, Rab11A, and Rab35 in regulation of smooth muscle contraction. Promotion of smooth
muscle contraction has been suggested for Ras in vascular smooth muscle and ARF6 in prostate smooth muscle. Inhibition of smooth muscle
contraction has been suggested for Ras in internal anal sphincter smooth muscle and for Rap1b and Rab11A in vascular smooth muscle. For
Rab35, a role in IL-17-induced airway hypercontractility has been suggested. GTPases with a pro-contractile role are marked by green colour, and
GTPases with an anti-contractile function by red colour. Ca2+, calcium
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secinH3, on smooth muscle contraction have been recently examined
in human prostate tissue. SecinH3 inhibited contractions of human
prostate tissues induced by the α1-adrenoceptor agonists phenyleph-
rine and noradrenaline, as well as neurogenic contractions induced by
electric field stimulation, or by endothelins 1 and 3 and U46619
(Herlemann et al., 2018). This was paralleled by inhibition of ARF6
activity in prostate tissues, whereas RhoA or Rac1 were not affected
by secinH3 (Herlemann et al., 2018). This pointed for a first time to a
role of ARF6 in promotion of smooth muscle contraction (Table 2).
With NAV2729, an inhibitor with assumed specificity for ARF6
has become available (Yamauchi, Miura, & Kanaho, 2017; Yoo
et al., 2016). Its effects on smooth muscle contraction have been
recently examined in human prostate tissues. NAV2729 inhibited neu-
rogenic, α1-adrenoceptor and endothelin induced smooth muscle con-
tractions of these tissues (Q. Yu, Gratzke, Wang, Li, et al., 2019).
Again, this was paralleled by inhibition of ARF6, but not of ARF1,
Rac1 or RhoA (Q. Yu, Gratzke, Wang, Li, et al., 2019). A participation
of ARF1 in regulation of smooth muscle contraction was furthermore
excluded by lacking effects of brefeldin A, which may inhibit ARF1,
but not ARF6 (Q. Yu, Gratzke, Wang, Li, et al., 2019). In addition to
α1-adrenoceptor and neurogenic contractions, NAV2729 inhibited
U46619 but not endothelin-1 induced contractions, what may point
to a divergent ARF6-mediated regulation of these contractions in
human prostate smooth muscle (Q. Yu, Gratzke, Wang, Li,
et al., 2019). ARF6 was not activated in prostate tissues by stimulation
with α1-adrenoceptor agonists, so that promotion of smooth muscle
contraction by the NAV2729-sensitive mechanisms takes most likely
place without ARF6 activation by contractile receptors (Q. Yu,
Gratzke, Wang, Li, et al., 2019). NAV2729 did not affect phosphoryla-
tion of MYPT1 or MLCs, so that such mechanisms are unlikely to
account for the inhibitory effects of NAV2729 on prostate smooth
muscle contraction (Q. Yu, Gratzke, Wang, Li, et al., 2019). Rather, the
effect may be caused by a breakdown of actin organization, which
was observed in prostate stromal cells in response to NAV2729
(Q. Yu, Gratzke, Wang, Li, et al., 2019).
Together, it appears possible that a cytohesin-2/ARF6-dependent
mechanism promotes smooth muscle contraction in the prostate
(Figure 2). Evidence for a similar role in other organs is still missing at
the present stage. Certainly, a definitive role of ARF6 for smooth mus-
cle contraction still needs to be confirmed by knockout models. How-
ever, the anti-proliferative effect of NAV2729 was mimicked by
silencing of ARF6 expression, so that similar results for contraction
appear possible (Q. Yu, Gratzke, Wang, Li, et al., 2019).
7 | RAP GTPASES IN SMOOTH MUSCLE
CONTRACTION
The role of Rap1b for vascular smooth muscle contraction has been
suggested recently (Table 2). Rap1b knockout mice showed arterial
hypertension, which was explained by increased vascular tone
(Lakshmikanthan et al., 2014). In contractility studies, aortic tissues
from Rap1b knockout mice showed enhanced contractile responses
to phenylephrine, angiotensin II and U46619 compared with aortas
from corresponding wild types (Lakshmikanthan et al., 2014). This was
paralleled by increased MYPT1 phosphorylation (suggestive for inhibi-
tion of MLCP) and increased MLC phosphorylation (Lakshmikanthan
et al., 2014). Accordingly, it has been concluded that Rap1 suppresses
contraction of vascular smooth muscle cells by negative control of cal-
cium sensitivity and that Rap1 may be activated through cAMP/Epac
(Figure 2; Lakshmikanthan et al., 2014). It should be noted that this
study proposed an endothelium-dependent mechanism of Rap1,
which contributes to control of vascular tone in parallel to Rap1 in
smooth muscle cells (Lakshmikanthan et al., 2014). Thus, in endothe-
lial cells, Rap1 may be involved in production of NO, which subse-
quently contributes to vasorelaxation of adjacent smooth muscle cells
(Lakshmikanthan et al., 2014). Further evidence from endothelium
denuded pig coronary arteries and cultured smooth muscle cells
suggested the role of Rap1 in endothelium independent vascular
smooth muscle relaxation, by Epac-mediated inhibition of RhoA activ-
ity and subsequently reduced MLC phosphorylation in smooth muscle
cells (X. Yu et al., 2017; Zieba et al., 2011). Certainly, the available
chain of evidence in fact supports this role, although indirectly as it
did not include Rap1-specific compounds or knockout models.
8 | RAB GTPASES IN SMOOTH MUSCLE
CONTRACTION
Evidence has been provided that Rab GTPases may regulate smooth
muscle contraction in vascular and airway smooth muscle (Table 2).
Generally, Rab GTPases are central players in intracellular trafficking,
including transport of proteins from intracellular compartments to the
surface, or shuttling between vesicles and cytosolic destinations
(Zhen & Stenmark, 2015). In rat arteries, Rab11A was suggested to
play an anti-contractile role, which is based on assembly of large-
conductance calcium-activated potassium channels (KCa1.1, syn. BK
channels; Figure 2; Zhai, Leo, & Jaggar, 2017). Opening of KCa1.1
channels causes hyperpolarization and is involved in smooth muscle
relaxation and counteracts contraction (Hennenberg, Trebicka,
Sauerbruch, & Heller, 2008). The complete channel is composed of
pore-forming BKα subunits and auxiliary β1 subunits (Zhai, Leo, &
Jaggar, 2017). Trafficking of β1 subunits to the cell surface is required
for assembly of KCa1.1 channels and was shown to depend on Rab11A
in myocytes of rat cerebral arteries (Zhai et al., 2017). Phosphorylation
of Rab11A serine 117 results in its inactivation and was found to be
induced by endothelin-1 and subsequent PKC activation in these
myocytes (Zhai et al., 2017). Consequently, transfection of rat cerebral
artery tissue with a phosphorylation-resistant Rab11A mutant (i.e. a
mutant, which cannot be inactivated by endothelin-1/PKC) resulted in
reduced endothelin-1-induced contractions in pressurized myography
(Zhai et al., 2017). Thus, endothelin-1-induced contraction of arterial
smooth muscle may be (at least partially) mediated by inactivation of
Rab11A and subsequently reduced current across BK channels.
In mice, Rab35 was suggested to mediate IL-17A induced airway
hyperresponsiveness (Figure 2; Bulek et al., 2019). Thus, challenging
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mice with IL-17A resulted in hyperresponsiveness of tracheal strips to
the cholinergic agonist methacholine in organ bath studies, which was
reflected by increased contractile forces during construction of con-
centration response curves for methacholine (Bulek et al., 2019). The
development of this hyperresponsiveness by IL-17A was completely
prevented by silencing of Rab35 expression by infection of mice with
a Rab35 shRNA coding lentivirus (Bulek et al., 2019). Interestingly, this
role of Rab35 seems to be rather specific for the development of air-
way hyperresponsiveness than representing a general regulatory
mechanism of airway contraction, as the contractile responses to
methacholine in mice with silenced Rab35 contraction was still pre-
served and resembled that of mice without IL challenge and without
Rab35 silencing (Bulek et al., 2019).
9 | CONCLUSIONS
The role of monomeric GTPases other than RhoA for regulation of
smooth muscle contraction has been suggested for vascular, airway,
bladder, prostate and gastrointestinal smooth muscle. Non-RhoA
GTPases with proposed roles in regulation of smooth muscle tone
include Rac1, Cdc42, Ras, ARF6, Rap1, Rab11A and Rab35. Available
evidence is based on functional studies addressing contractility
in vitro, or organ-specific functions in vivo. The best characterized
GTPase in this context is Rac1. Rac1 may promote vascular, airway,
bladder, prostate and gastrointestinal smooth muscle contraction,
whereas anti-contractile functions of Rac1 were suggested in airways
and vessels. Roles of Cdc42 and Ras to promote airway and vascular
smooth muscle contraction have been suggested early, whereas later
studies suggested an opposing function of Ras at gene expression
level, resulting in Ras-mediated reduction of smooth muscle contrac-
tion by suppression of Rho kinase expression. Evidence for regulation
of smooth muscle contractility by ARF6, Rap1, Rab11A and Rab35
has been provided recently, pointing to a pro-contractile role of ARF6
in prostate smooth muscle, anti-contractile functions of Rap1 and
Rab11A in vascular smooth muscle contraction and promotion of air-
way hypercontractility by Rab35. The role of non-RhoA GTPases for
regulation of smooth muscle contractility constitutes a promising and
innovative research field, which requires further attention to complete
the understanding of these (and other) GTPases in regulation of
smooth muscle tone and associated diseases. Opposing roles in differ-
ent smooth muscle types may reflect the complexity and organ-
specific diversity of molecular mechanisms underlying regulation of
smooth muscle contraction. Divergent findings for Rac1 in the same
smooth muscle type may highlight the character of GTPases as that
what they are commonly termed molecular switches, being capable to
change signalling in bidirectional functions.
Nomenclature of targets and ligands
Nomenclature of key protein targets and ligands in this article con-
form with the IUPHAR/BPS Guide to PHARMACOLOGY, as archived
in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander,
Christopoulos, et al., 2019; Alexander, Fabbro, et al., 2019; Alexander,
Kelly, et al., 2019; Alexander, Mathie, et al., 2019) or recommended
by the IUPHAR/BPS Guide to PHARMACOLOGY database group.
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